News · News

HHS eases enforcement on compounding six peptides

By Ali Peivandizadeh, business growth and AI implementation specialist.

Published Nov 13, 2026 · Last checked Nov 13, 2026 · Last changed Nov 13, 2026

The short version

HHS said it does not intend to act against licensed pharmacies and physicians that compound six named peptides, if they meet set conditions.

For: Beauty and cosmetic practices, weight loss and wellness clinics. Owner, medical director.

The facts

HHS announced the interim policy on Oct 30, 2026. Law firm Morgan Lewis described it on Nov 10, 2026.
The six peptides are BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500.
The conditions include one peptide in each product, a maker registered with the FDA, and a valid prescription for a specific patient.
The policy does not change the law. HHS or the FDA can change the policy later.
It does not cover imported peptides. The FDA's advertising rules still apply.
State medical and pharmacy boards keep their own rules, and those can differ.
The FDA sent more than 100 enforcement letters about compounded drug advertising in 2026.

The federal enforcement risk changed for six peptides under set conditions. State board rules and advertising rules stayed the same.